# PHARMACEUTICAL 2024

## Madrigal Pharmaceuticals INC
## Rank 171 of 309



RealRate

# PHARMACEUTICAL 2024

## Madrigal Pharmaceuticals INC
## Rank 171 of 309

The relative strengths and weaknesses of Madrigal Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Madrigal Pharmaceuticals INC compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 58% points.The greatest weakness of Madrigal Pharmaceuticals INC is the variable Net Income, reducing the Economic Capital Ratio by 47% points.

The company's Economic Capital Ratio, given in the ranking table, is 192%, being 21% points below the market average of 213%.

| Input Variable | Value in 1000 USD |
|---|---|
| Assets, Current | 637,281 |
| Cost of Goods Sold | 0 |
| Intangible Assets | 0 |
| Liabilities, Current | 118,548 |
| Liabilities, Non-Current | 116,666 |
| Other Assets | 1,713 |
| Other Compr. Net Income | 500 |
| Other Expenses | 285,062 |
| Other Liabilities | 0 |
| Other Net Income | 19,578 |
| Other Revenues | 0 |
| Property and Equipment | 1,553 |
| Research and Development | 272,350 |
| Selling, General and Administrative Expense | 108,146 |

| Output Variable | Value in 1000 USD |
|---|---|
| Assets | 640,547 |
| Liabilities | 235,214 |
| Expenses | 665,558 |
| Revenues | 0 |
| Stockholders Equity | 405,333 |
| Net Income | -645,980 |
| Comprehensive Net Income | -645,730 |
| BaseVar | 780,698 |
| ECR before LimitedLiability | 54% |
| Economic Capital Ratio | 192% |